Scleroderma Foundation's 13th Annual National Patient Education Conference Is Here PDF Print E-mail
Wednesday, 06 July 2011 10:31
Nearly 600 people are anticipated to visit the heart of San Francisco Friday, July 8, through Sunday, July 10, for the Scleroderma Foundation's 13th Annual National Patient Education Conference. Patients, family members, caregivers, doctors and other health care professionals representing 40 states, the District of Columbia, Canada and Mexico will converge at the Hilton San Francisco Union Square for this engaging and educational event that focuses on scleroderma, a rare autoimmune disease.

This year's conference features a variety of workshops hosted by leading scleroderma researchers and medical professionals. Andreas Baxevanis, Ph.D., will give the opening keynote address on the promise of genomics and genome-based personal health care in disease management. James Lemons, Ed.D., will present the closing keynote on "Pain – The Psychology and Physiology: There is Hope." Dr. Baxevanis is Assistant Director for Computational Bioscience, Office of Intramural Research at the National Institutes of Health (NIH), and Associate Investigator, Division of Intramural Research at the National Human Genome Research Institute in Bethesda, Md. Dr. Lemons is the director of The Lemons Center for Behavioral Pain Management in Lenexa, Kan., and a medical psychologist.

Other conference highlights include:
  • Fifty-six workshops and panel discussions for patients, family members and caregivers.
  • Special sessions for children with scleroderma and their families.
  • Representatives from the University of Texas Scleroderma Family Registry and DNA Repository and the University of Texas Southwestern Morphea Registry and DNA Repository will be at the conference seeking interested individuals to serve as donors and controls for scleroderma research.
  • Annual Awards Banquet to honor Scleroderma Foundation members, volunteers and chapters of the Foundation for their dedication and work to advance the mission of the Scleroderma Foundation, and bring awareness to the issues facing the scleroderma patient community.

For more information about scleroderma and the National Patient Education Conference, visit www.scleroderma.org.

 
More articles :

» Dermatomyositis

Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness. Dermatomyositis’ cardinal symptom is a skin rash that precedes or...

» Treatment for Pulmonary Arterial Hypertension Cleared

has recently reported in its that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to...

» The Incidence Of Prostate Cancer Higher In Men With Autoimmune Diseases

Men with autoimmune diseases have a higher incidence of (PCa) than those without those diseases, according to study findings presented at the annual meeting.Using the National Inpatient Sample database, researchers obtained data on 189,290 men...

» Sildenafil Reduces Raynaud's Frequency in Systemic Sclerosis Patients

Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of in patients with limited cutaneous systemic sclerosis (lcSSc), also known as . The double-blind, placebo-controlled...

» Two Problems That People With Scleroderma Face: Malabsorption and Inflammation

According to , many doctors agree that starts with inflammation, and its progress depends on how much inflammation continues to occur in the body. That's one reason some doctors recommend that patients with any sort of inflammatory disease such as...

» Calcinosis

Background:The Foundation has recently received some feedback from some members of the public asking for more information regarding the condition known as Calcinosis. As part of our efforts we sought to provide a brief, yet informative insight into...